Enoxaparin in ACS

More documents

Recommendations

Info

Antithrombin therapy with a strategy of ENOXis superior to the standard strategy of UFH inSTEMI patients undergoing pharmacologicreperfusion across the spectrum of lytics usedin ExTRACT-TIMI 25
New Data from ExTRACT-TIMI 251YEAR FOLLOW UPESC 2007To determine if the benefits of theENOX strategy over the UFHstrategy were sustained through 1 yr.Methods• Telephone Tl follow-up fll at 6 and 12 monthsDeath from any causeRecurrent MIStroke→ 1yrfollow-up available on 99% of ITT cohort• CRF documentationSame endpoint pages as main trial Investigator-reported• Statistical Analysis:Intention-to-treat, treat, Log Rank
Page 1 and 2: Enoxaparin in ACSWhen evidence meet
Page 3 and 4: o DefinitionsAgendao Is UFH w/o dis
Page 5 and 6: Superiority ofEnoxaparin over UFHEv
Page 7 and 8: Coronary patency (TIMI flow 2 or 3)
Page 9 and 10: Enoxaparin versus UFH for STEMIOne
Page 11: No Increase in ICHents% Ev10UFHENOX
Page 15 and 16: Net Clinical BenefitDeath/MI/Disabl
Page 17 and 18: Summary-23. Net clinical benefit si
Page 19 and 20: Enoxaparin and GP IIb/IIIa inhibito
Page 21 and 22: NICE -3Objectiveso To assess the sa
Page 23 and 24: o DefinitionsAgendao Is UFH w/o dis
Page 25 and 26: Clexane in ACS - My ApproachACSCons
Page 27: Egyptian Guidelines for themanageme

Enoxaparin in ACS

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?